Medicines to remain with European Commission health directorate
BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g6514 (Published 29 October 2014) Cite this as: BMJ 2014;349:g6514- Rory Watson
- 1Brussels
The incoming European Commission president, Jean-Claude Juncker, has had to backtrack over his earlier decision to transfer responsibility for medicines and the European Medicines Agency away from the commission’s health directorate to its industry and enterprise directorate.
The initial announcement in September led to widespread concern in the public health sector. It feared that industry and commercial interests would weigh more heavily than patient safety and medical considerations when future legislation or drug authorisation was being considered.1
The proposed transfer prompted high profile protests as members of the European Parliament, led by the British Labour member Glenis Willmott, non-governmental organisations, and …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.